Trial Profile
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil(R)) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 14 Mar 2014 Trial status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 02 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.